Complexin-2 (CPLX2) as a potential prognostic biomarker in human lung high grade neuroendocrine tumors

Komatsu, Hiroaki; Kakehashi, Anna; Nishiyama, Noritoshi; Izumi, Nobuhiro; Mizuguchi, Shinjiro; Yamano, Shotaro; Inoue, Hidenari; Hanada, Shoji; Chung, Kyukwang; Wei, Min; Suehiro, Shigefumi; Wanibuchi, Hideki

doi:10.3233/cbm-130336

Cited by 19 publications

(15 citation statements)

References 40 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have reported that CPLX2 plays a key role in maintaining normal neurological function, while its downregulation changes the neurotransmitter release that is sufficient to cause significant behavioral abnormalities, such as depression (10). Komatsu et al (14) reported that CPLX2 was strongly positive in 16.3% of large cell neuroendocrine carcinomas of the lung and small cell carcinomas of the lung, but completely negative in all adjacent non-cancerous tissues and in non-small cell lung carcinomas. They also demonstrated that positive CPLX2 expression was associated with lymph vessel invasion (P = 0.016), pathological stage (P = 0.031) and poor disease-specific survival (P = 0.004) in these patients.…”

Section: Conflict Of Interestmentioning

confidence: 99%

Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach

et al. 2017

View full text Add to dashboard Cite

The gene mutation and expression profiles of gastric neuroendocrine carcinoma (NEC) have not been comprehensively determined. Here, we examined the gene mutation and expression profiles of NEC using whole exome sequencing (WES) and microarray analysis. Six patients with gastric NEC and 13 with gastric adenocarcinoma (GAD) were included in this study. Single nucleotide variants were compared and multivariate statistical investigation with orthogonal partial least squares discriminant analysis (OPLS-DA) was performed to compare the difference in expression profiles between NEC and GAD. NEC showed a significantly higher mutation rate than GAD and the percentage difference in the mutation pattern of NEC compared with GAD was 92.8%. OPLS-DA clearly discriminated between NEC and GAD. We identified 35 genes, including CPLX2 (Complexin 2), which were expressed more strongly in NEC than in GAD, of which 14 were neural-related. Immunohistochemical analysis showed the strong expression of CPLX2 in all NECs, versus expression in only 2 of 13 GADs. Gastric NEC had a specific mutation pattern with a significantly higher gene mutation rate than GAD, and completely differed from GAD on the basis of gene expression profile. CPLX2 might be a potential novel biomarker for the diagnosis of NEC.

show abstract

Section: Conflict Of Interestmentioning

confidence: 99%

Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach

et al. 2017

View full text Add to dashboard Cite

show abstract

“…After screening, we found 13 common genes in four groups of DEGs. Komatsu et al [26] studied clinical biomarkers of pulmonary neuroendocrine tumors (LNET) and found that CPLX2 was strongly positive in 16.3% of the examination groups. Importantly, positive CPLX2 expression is associated with lymphatic invasion, pathological staging, and adverse disease-specific survival in LNET patients.…”

Section: Discussionmentioning

confidence: 99%

“…Importantly, positive CPLX2 expression is associated with lymphatic invasion, pathological staging, and adverse disease-specific survival in LNET patients. It was finally concluded that CPLX2 is a novel clinical biomarker for LNET [26]. In the study of breast cancer diagnostic markers, Fu et al [27] found that changes in gene expression such as DPEP1 may lead to cancer progression.…”

Section: Discussionmentioning

confidence: 99%

Time series expression pattern of key genes reveals the molecular process of esophageal cancer

2020

View full text Add to dashboard Cite

Correspondence: Yurong Sun (supiaoy66@163.com) Background: Esophageal cancer is one of the most poorly diagnosed and fatal cancers in the world. Although a series of studies on esophageal cancer have been reported, the molecular pathogenesis of the disease is still elusive. Aim: To investigate the molecular process of esophageal cancer comprehensively and deeply. Methods: Differential expression analysis was performed to identify differentially expressed genes (DEGs) in different stages of esophageal cancer. Then exacting gene interaction modules and hub genes were identified in module interaction network. Further, though survival analysis, methylation analysis, pivot analysis, and enrichment analysis, some important molecules and related function or pathway were identified to elucidate potential mechanism in esophageal cancer. Results: A total of 7457 DEGs and 14 gene interaction modules were identified. These module genes were significantly involved in the positive regulation of protein transport, gastric acid secretion, insulin-like growth factor receptor binding and other biological processes (BPs), as well as p53 signaling pathway, ERBB signaling pathway and epidermal growth factor receptor (EGFR) signaling pathway. Then, transcription factors (TFs) (including HIF1A) and ncRNAs (including CRNDE and hsa-mir-330-3p) significantly regulate dysfunction modules were identified. Further, survival analysis showed that GNGT2 was closely related to survival of esophageal cancer. And DEGs with strong methylation regulation ability were identified, including SST and SH3GL2. Conclusion: These works not only help us to reveal the potential regulatory factors in the development of disease, but also deepen our understanding of its deterioration mechanism.

show abstract

“…It plays a positive role in Ca 2þ -triggered exocytosis by facilitating vesicle priming [27]. Complexin-2 is regarded as a potential prognostic biomarker in human lung highgrade neuroendocrine tumors [28].…”

Section: Quantitative Proteomic Analyses Of A549 Treated With Lip Andmentioning

confidence: 99%

Quantitative proteomic analysis to the first commercialized liposomal paclitaxel nano-platform Lipusu revealed the molecular mechanism of the enhanced anti-tumor effect

Zhao

Fan

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

The first nano-platform commercialized as a drug delivery system was a liposomal formulation. The application of liposome technology resolved the issues of paclitaxel (PTX) insolubility and eliminated the use of solvents causing toxic side-effects, which enabled to apply higher drug doses leading to an enhanced drug efficacy. The growth-inhibitory activity of liposome-encapsulated PTX was retained in vitro against a variety of tumor cell. To investigate the drug efficacy in the system biological level, quantitative proteomic analysis was employed to study the molecular mechanism of the anti-tumor effect of Lipusu (lip) compared with PTX on lung cancer cell A549. The functions of the differential expressed proteins were correlated to the negative effect to cell proliferation due to regulation of hippo pathway and prolonged cell cycle, as well as inhibitory cell exocytosis, which would cause the aggregation of free PTX. This investigation focused on the direct biological effect of lip to cancer cells. It was different from pharmaceutical issues about drug exposure, delivery and distribution which were widely investigated in other traditional studies. It was the first study about the drug effect of lip from the global molecular biological aspect.

show abstract

Complexin-2 (CPLX2) as a potential prognostic biomarker in human lung high grade neuroendocrine tumors

Cited by 19 publications

References 40 publications

<b>Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the </b><b>stomach </b>

<b>Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the </b><b>stomach </b>

Time series expression pattern of key genes reveals the molecular process of esophageal cancer

Quantitative proteomic analysis to the first commercialized liposomal paclitaxel nano-platform Lipusu revealed the molecular mechanism of the enhanced anti-tumor effect

Contact Info

Product

Resources

About